CTKB Strangle Strategy
CTKB (Cytek Biosciences, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems.
CTKB (Cytek Biosciences, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $605.7M, a beta of 1.17 versus the broader market, a 52-week range of 3.28-6.18, average daily share volume of 1.2M, a public-listing history dating back to 2021, approximately 682 full-time employees. These structural characteristics shape how CTKB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.17 places CTKB roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on CTKB?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
CTKB snapshot
As of August 14, 2026, spot at $4.76, ATM IV 24.80%, IV rank 4.99%, expected move 7.11%. The strangle on CTKB below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on CTKB specifically: CTKB IV at 24.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CTKB strangle, with a market-implied 1-standard-deviation move of approximately 7.11% (roughly $0.34 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CTKB expiries trade a higher absolute premium for lower per-day decay. Position sizing on CTKB should anchor to the underlying notional of $4.76 per share and to the trader's directional view on CTKB stock.
CTKB strangle setup
The CTKB strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CTKB at $4.76 on that close, the first option leg uses a $5.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CTKB chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CTKB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.00 | N/A |
| Buy 1 | Put | $4.52 | N/A |
CTKB strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CTKB strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CTKB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CTKB
Strangles on CTKB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTKB chain.
CTKB thesis for this strangle
The market-implied 1-standard-deviation range for CTKB extends from approximately $4.42 on the downside to $5.10 on the upside. A CTKB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CTKB IV rank near 4.99% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CTKB at 24.80%. As a Healthcare name, CTKB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CTKB-specific events.
CTKB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CTKB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CTKB alongside the broader basket even when CTKB-specific fundamentals are unchanged. Always rebuild the position from current CTKB chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CTKB?
- A strangle on CTKB is the strangle strategy applied to CTKB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CTKB stock at $4.76 on the most recent close, the strikes shown on this page are snapped to the nearest listed CTKB chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CTKB strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CTKB strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 24.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CTKB strangle?
- The breakeven for the CTKB strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CTKB market-implied 1-standard-deviation expected move in the same options snapshot is approximately 7.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CTKB?
- Strangles on CTKB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTKB chain.
- How does current CTKB implied volatility affect this strangle?
- CTKB ATM IV is at 24.80% with IV rank near 4.99%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.